230 related articles for article (PubMed ID: 30623243)
1. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
3. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.
Young LR; Vandyke R; Gulleman PM; Inoue Y; Brown KK; Schmidt LS; Linehan WM; Hajjar F; Kinder BW; Trapnell BC; Bissler JJ; Franz DN; McCormack FX
Chest; 2010 Sep; 138(3):674-81. PubMed ID: 20382711
[TBL] [Abstract][Full Text] [Related]
5. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
6. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
8. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
Chang WY; Cane JL; Blakey JD; Kumaran M; Pointon KS; Johnson SR
Respir Res; 2012 Apr; 13(1):34. PubMed ID: 22513045
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
12. The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.
Song X; Cai H; Peng W; Chen K; Abuduxukuer Z; Zeng Y; Zhu G; Lu C; Chen Y; Wang J; Ye L; Jin M
Respir Res; 2024 Jan; 25(1):57. PubMed ID: 38267973
[TBL] [Abstract][Full Text] [Related]
13. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.
Radzikowska E; Jaguś P; Skoczylas A; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Pol Arch Med Wewn; 2013; 123(10):533-8. PubMed ID: 24060688
[TBL] [Abstract][Full Text] [Related]
14. Involvement of lymphatics in lymphangioleiomyomatosis.
Glasgow CG; Taveira-DaSilva A; Pacheco-Rodriguez G; Steagall WK; Tsukada K; Cai X; El-Chemaly S; Moss J
Lymphat Res Biol; 2009 Dec; 7(4):221-8. PubMed ID: 20143921
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).
Baldi BG; Araujo MS; Freitas CS; da Silva Teles GB; Kairalla RA; Dias OM; Pereira DA; Pimenta SP; Carvalho CR
Lung; 2014 Dec; 192(6):967-74. PubMed ID: 25201087
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
17. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
18. Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis.
Di Marco F; Terraneo S; Dias OM; Imeri G; Centanni S; Rinaldo RF; Giuliani L; Lesma E; Palumbo G; Wanderley M; Ribeiro Carvalho CR; Guedes Baldi B
Respir Med; 2020 Jul; 168():105993. PubMed ID: 32469709
[TBL] [Abstract][Full Text] [Related]
19. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Shawker T; Glasgow CG; Stylianou M; Moss J
Chest; 2015 Oct; 148(4):1027-1033. PubMed ID: 26066372
[TBL] [Abstract][Full Text] [Related]
20. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
